Clinical, epidemiologic and molecular data have clearly demonstrated that certain human papillomavirus (HPV) types, those so-called high risk, are the etiological agents of cervical cancer (zur Hausen ...
Papillomaviruses that are associated with in situ carcinoma are termed ‘high-risk’, and their E6 proteins, whether they are derived from human or other animal papillomaviruses, have been shown to be ...
The utilization of patient-derived organoids as a platform for predicting the efficacy of anti-cancer drugs: Chemotherapy, targeted therapy, and immunotherapy. This is an ASCO Meeting Abstract from ...
Infection with HPV16, a high-risk human papillomavirus (HPV), can cause cervical cancer in humans. These infections carry a high risk of morbidity and mortality globally in females. This study aimed ...
The molecular mechanisms through which host cells are transformed by HPV are well known, and are executed largely via the E6 and E7 viral oncoproteins carried in the genomes of oncogenic HPV strains.
Using animal models, researchers uncovered how cervical and throat cancers linked to the human papillomavirus evade the immune system, opening the door to new treatment. The most common cancer-causing ...
Human papillomavirus (HPV), particularly the high-risk HPV16 subtype, is a major driver of certain cancers, including cervical, oropharyngeal, anal and penile cancers. The E6 and E7 proteins produced ...
An international group of researchers has found that antibodies to the human papilloma virus type 16 (HPV16) develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, ...
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the ...
The most common cancer-causing strain of human papillomavirus (HPV), HPV16, undermines the body's defenses by reprogramming immune cells surrounding the tumor, according to new research from the Keck ...
An international group of researchers has found that antibodies to the human papilloma virus type 16 (HPV16) develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results